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ABSTRACT
Objective To quantify associations of chronic kidney
disease stages with major cardiovascular disease and
non-vascular mortality in the general adult population.
Design Prospective population based cohort study.
Setting Reykjavik, Iceland.
Participants 16958 people aged 33-81 years without
manifest vascular disease and with available information
on stage of chronic kidney disease (defined by both
estimatedglomerularfiltrationrateandurinaryprotein)at
study entry.
Main outcome measures Hazard ratios for time to major
coronary heart disease outcomes and mortality.
Results 1210 (7%) of participants had chronic kidney
disease at entry. During a median follow-up of 24 years,
4010 coronary heart disease outcomes, 559 deaths from
stroke, and 3875 deaths from non-vascular causes were
recorded. Compared with the reference group (estimated
glomerular filtration rate 75-89 ml/min/1.73 m
2 and no
proteinuria), people with lower renal function within the
normal range of glomerular filtration rate did not have
significantly higher risk of coronary heart disease. By
contrast, in 1210 (7%) participants with chronic kidney
diseaseat entry,hazardratiosforcoronaryheartdisease,
adjusted for several conventional cardiovascular risk
factors, were 1.55 (95% confidence interval 1.02 to 2.35)
for stage 1, 1.72 (1.30 to 2.24) for stage 2, 1.39 (1.22 to
1.58) for stage 3a, 1.90 (1.22 to 2.96) for stage 3b, and
4.29 (1.78 to 10.32) for stage 4. Information on chronic
kidney disease increased discrimination and
reclassification indices for coronary heart disease when
added to conventional risk factors (P<0.01). The
incremental gain provided by chronic kidney disease was
lower than that provided by diabetes or smoking (C index
increases of 0.0015, 0.0024, and 0.0124 respectively).
Hazardratioswithchronickidneydiseasewere0.97(0.82
to 1.15) for cancer mortality and 1.26 (1.07 to 1.50) for
other non-vascular mortality.
ConclusionsInpeoplewithoutmanifestvasculardisease,
even the earliest stages of chronic kidney disease are
associated with excess risk of subsequent coronary heart
disease. Assessment of chronic kidney disease in
addition to conventional risk factors modestly improves
prediction of risk for coronary heart disease in this
population. Further studies are needed to investigate
associations between chronic kidney disease and non-
vascular mortality from causes other than cancer.
INTRODUCTION
End stage renal failure is known to be associated with
striking excesses of cardiovascular and all cause
mortality.
1Strongassociationshavealsobeenreported
between non-dialysis dependent chronic kidney dis-
ease and such outcomes in patients with ischaemic
cardiovascular diseases, heart failure, and high blood
pressure.
2-4 Such observations have led to recommen-
dations by scientific and professional bodies that
patients with manifest cardiovascular disease should
be screened for evidence of kidney disease and that
patients with chronic kidney disease should be
regarded as at very high risk of coronary heart
disease.
56 In the general adult population, however,
chronic kidney disease often goes undiagnosed
becauseitislargelyasymptomatic.
7Severalpopulation
based prospective studies have reported on associa-
tions between renal function and vascular disease.
8-15
However,manysuchstudieshavelackedconcomitant
assessment of estimated glomerular filtration rate and
urinary protein status or involved less than 10 years of
follow-up (the time horizon used in most clinical
cardiovascularriskscores),omittedmeasuresofdiscri-
mination or reclassification of risk to help in judging
the incremental predictive value of assessing chronic
kidney disease, or involved some combination of
these limitations. Hence, determining the potential
value of assessment ofchronic kidney diseasein popu-
lation-wide cardiovascular disease screening pro-
grammes, such as the National Health Service health
check in the United Kingdom,
16 has been difficult.
Wereportontheincrementalvalueofassessmentof
chronic kidneydiseaseforpredictionof riskforcoron-
ary heart disease in a population based prospective
study of people without manifest vascular disease
who have been monitored, on average, for almost a
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havecomparedthepredictiveabilityofchronickidney
disease with that of smoking and diabetes.
METHODS
Participants, measurements, and end points
The Reykjavik study has been described in detail
previously.
17 Briefly, all men born between 1907 and
1934andallwomenbornbetween1908and1935who
were resident in Reykjavik, Iceland, and its adjacent
communities on 1 December 1966 were identified in
the national population register and then invited to
participate in the Reykjavik study during five stages
of recruitment between 1967 and 1991, yielding a
total of 9134 male and 9769 female participants (72%
responserate).Allparticipantsgaveinformedconsent.
Nurses administered questionnaires, made physical
measurements, recorded an electrocardiogram, and
collected urine and fasting venous blood samples at
baseline.Creatininemeasurementsweremadeatbase-
line within days of the initial examination by using the
Jaffe method.
18 Values of estimated glomerular filtra-
tion rate were calculatedwith the four variablemodifi-
cation of diet in renal disease (MDRD
19) prediction
equation and expressed as ml/min/1.73 m
2 (with sub-
sidiary analyses using estimated glomerular filtration
rate calculated with the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPI
20) equation).
Serum creatinine concentrations could not be recali-
bratedtothemoreaccurateisotopedilutionmassspec-
trometry standard. Presence of proteinuria was
assessed at baseline with a urinary dipstick (Bayer
Diagnostics Ames Multistix or Boehringer Mannheim
Multistix). Results were considered positive if the dip-
stick test was 1+ or greater. Other analytes were mea-
sured by using standard methods, as described
previously.
21 As high density lipoprotein cholesterol
concentrations were available for only a small subset
of participants, Framingham based models were not
used.
All participants have been monitored by central
registries for occurrence of non-fatal myocardial
infarction (on the basis of multinational monitoring of
trends and determinants in cardiovascular disease
(MONICA)orsimilarcriteria)orcoronaryrevascular-
isation (coronary artery bypass grafting or
percutaneous transluminal coronary angioplasty)
until the end of 2005 and cause specific mortality (on
the basis of a death certificate with international classi-
ficationofdiseases(ICD)codes)untiltheendof2007.
22
Loss to follow-up has been about 0.6% to date. Cause
specific mortality was coded according to ICD-9 up to
December 1996 and ICD-10 subsequently (web table
A). Compared with a previous report in a subset of
participants,
23 this study used cohort-wide data on
both estimated glomerular filtration rate and protei-
nuria, as well as extended follow-up.
Statistical analysis
Principal analyses excluded participants with a history
of cardiovascular disease at entry (defined as coronary
heart disease, stroke, other heart diseases (such as
angina or valvular disease), or coronary revascularisa-
tion)orknowntobereceivingrenalreplacementtreat-
ment. Subsidiary analyses also excluded participants
with self reported diabetes mellitus or fasting blood
glucose of 7 mmol/l or above at entry. We defined
chronic kidney disease as either presence of protei-
nuria or estimated glomerular filtration rate <60 ml/
min/1.73 m
2, following the guidelines from the UK
National Institute for Health and Clinical Excellence
(NICE)(table 1)or,insubsidiaryanalyses,theKidney
Disease Outcomes Quality Initiative criteria.
2425 We
classified participants without chronic kidney disease
(estimated glomerular filtration rate ≥60 ml/min/1.73
m
2andabsenceofproteinuria)intothreegroupsonthe
basis of thresholds of estimated glomerular filtration
rate used in a previous study: 60-74, 75-89, and
≥90 ml/min/1.73 m
2.
13
The principal outcome was coronary heart disease,
defined as non-fatal or fatal myocardial infarction or
coronary revascularisation. We restricted analyses to
participants with complete information on relevant
covariates. Participants contributed only their first
non-fatal coronary heart disease outcomes or death
(that is, we did not include deaths preceded by non-
fatal myocardial infarction or coronary revascularisa-
tion). We calculated hazard ratios by using Cox pro-
portional models stratified by sex, using floating
risks.
26 Subsidiary analyses investigated the shape of
associations by dividing the data into fifths of baseline
values of estimated glomerular filtration rate, with
further subdivision of the lowest fifth into three more
groups,andusingregressionsplinemethods.Toassess
the prediction of risk for coronary heart disease with
chronic kidney disease in addition to several conven-
tional risk factors (age, sex, smoking, history of dia-
betes, systolic blood pressure, and total cholesterol),
we calculated measures of discrimination for censored
time to event data (Harrell’s C index) and reclassifica-
tion (net reclassification improvement and integrated
discriminationindexusing10yearriskcategoriesof0-
5%, 5-10%, 10-20%, and ≥20%).
27 We compared the
predictivegainprovidedbyassessmentofchronickid-
ney disease against that provided by information on
diabetes and smoking status, removing each of these
variables from a risk model containing several
Table 1 |Chronic kidney disease staging system
24
Stage
Glomerular filtration rate
(ml/min/1.73 m2) Description
1 ≥90 Normal or increased glomerular filtration rate, with other evidence of
kidney damage*
2 60-89 Slightdecreaseinglomerularfiltrationrate,withotherevidenceofkidney
damage*
3a 45-59 Moderate decrease in glomerular filtration rate, with or without other
evidence of kidney damage* 3b 30-44
4 15-29 Severe decrease in glomerular filtration rate, with or without other
evidence of kidney damage*
5 <15 Established renal failure
*Evidence of kidney damage defined in this analysis as evidence of proteinuria assessed with urinary dipstick.
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We used Stata version 11 for statistical analyses, with
two sided tests and P<0.05.
RESULTS
Baseline associations
The mean age of the 16958 participants was 53 (range
33-81; SD 9) years, 51% were female, and the mean
estimated glomerular filtration rate was 79 (14) ml/
min/1.73 m
2 (table 2). Six per cent (1016) of partici-
pantshadanestimatedglomerularfiltrationratebelow
60, 1.4% (241) had proteinuria, and 7% (1210) had
chronic kidney disease at entry (65 had stage 1, 129
had stage 2, 939 had stage 3a, 65 had stage 3b, and 12
had stage 4). People with chronic kidney disease had
higher mean levels of cardiovascular risk factors than
did people without chronic kidney disease, except for
smoking and male sex (table 2, web table B). During
383553 person years at risk (median follow-up 24
(interquartile range 17-31) years), 4010 coronary
heart disease outcomes, 559 deaths from stroke, 662
deaths from other vascular causes, and 3875 deaths
from non-vascular causes were recorded.
Hazard ratios with disease outcomes
Compared with the reference group (estimated glo-
merular filtration rate of 75-89 ml/min/1.73 m
2 and
without proteinuria), people at each clinically defined
stage of chronic kidney disease had higher risk of cor-
onary heart disease (fig 1 , table 3, web table C). This
relation was non-linear in shape, and the possibility
existedofaweaklypositivehazardratioinpeoplewith-
out chronic kidney disease who had an estimated glo-
merular filtration rate of 90 ml/min/1.73 m
2 or above.
Regression spline analyses yielded broadly similar
findings (web fig A). In analyses comparing people
with and without chronic kidney disease, the hazard
ratio for coronary heart disease was 1.53 (95% confi-
dence interval 1.36 to 1.71) after adjustment for age
and sex only; it was 1.45 (1.29 to 1.62) after further
adjustment for smoking status, history of diabetes, sys-
tolic blood pressure, body mass index, total choles-
terol, and triglycerides (“further adjustment”). In
analyses comparing people with and without protei-
nuria, the hazard ratio for coronary heart disease was
1.96(1.60to2.40)afteradjustmentforageandsexonly
and 1.72 (1.40 to 2.11) after further adjustment. The
hazard ratio for coronary heart disease with chronic
kidney disease was possibly higher in people with dia-
betes, but it did not vary considerably by other risk
factors recorded (web fig B). After further adjustment,
hazard ratios with chronic kidney disease were 1.21
(0.75 to 1.95) for ischaemic stroke, 1.18 (0.77 to 1.80)
for unclassified stroke, 1.02 (0.55 to 1.89) for haemor-
rhagicstroke,0.71(0.37to1.33)forotherdeathsattrib-
utedtocerebrovasculardisease,and1.22(0.89to1.66)
for other deaths from vascular disease (mainly heart
failure,cardiacarrhythmia,andpulmonaryembolism)
(fig 2).
Associationsbetweendifferentstagesofchronickid-
ney disease and the aggregate of non-vascular mortal-
ity were non-linear (fig 1, web fig A). Again, the
Table 2 |Demographic and clinical baseline characteristics by chronic kidney disease (CKD) status. Values are numbers (percentages) unless stated
otherwise
Characteristics Overall population (n=16 958) Non-CKD (n=15 748) CKD (n=1210) P value
Demographic factors
Mean (SD) age (years) 52.5 (8.6) 51.9 (8.3) 59.4 (9.8) <0.001
Male sex 8237 (48.6) 7848 (49.8) 389 (32.1) <0.001
Established risk factors
Current cigarette smokers 8013 (47.3) 7570 (48.1) 443 (36.6) <0.001
History of diabetes 400 (2.4) 351 (2.2) 49 (4.0) <0.001
Mean (SD)systolicblood pressure(mm Hg) 138 (22) (n=16 957) 138 (21) (n=15 747) 145 (25) <0.001
Mean(SD)diastolicbloodpressure(mmHg) 87 (12) (n=16 956) 86 (12) (n=15 746) 88 (13) <0.001
Mean (SD) body mass index (kg/m
2) 25.4 (3.9) (n=16 895) 25.3 (3.8) (n=15 696) 26.3 (4.4) (n=1199) <0.001
Blood based factors
Mean (SD) total cholesterol (mmol/l) 6.48 (1.16) (n=16 942) 6.46 (1.15) (n=15 734) 6.74 (1.28) (n=1208) <0.001
Mean (SD) log triglycerides (mmol/l) 0.02 (0.45) (n=16 447) 0.01 (0.44) (n=15 263) 0.16 (0.45) (n=1184) <0.001
Mean (SD) fasting glucose (mmol/l) 4.48 (0.74) (n=16 905) 4.47 (0.70) (n=15 698) 4.57 (1.08) (n=1207) <0.001
Mean (SD) log erythrocyte sedimentation
rate (mm/h)
1.90 (0.94) (n=16 066) 1.88 (0.93) (n=14 916) 2.13 (0.97) (n=1150) <0.001
Socioeconomic factors
Non-manual occupation 5841/10 889 (53.6) 5441/10 260 (53.0) 400/629 (63.6) <0.001
Education beyond high school 2558 (15.1) 2394 (15.2) 164 (13.6) 0.123
Renal markers
Mean (SD) creatinine (mg/dl) 0.95 (0.18) 0.93 (0.15) 1.17 (0.33) <0.001
Mean (SD) eGFR (MDRD equation) 78.7 (14.4) 80.2 (13.2) 58.7 (14.8) <0.001
Positive urine protein 241 (1.4) 0 241 (19.9) <0.001
eGFR=estimated glomerular filtration rate; MDRD=modification of diet for renal disease.
16 369 participants had complete information on smoking status, history of diabetes, total cholesterol, triglycerides, systolic blood pressure, and body mass index.
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peoplewithoutchronickidneydiseasewhohadanesti-
mated glomerular filtration rate of 90 ml/min/1.73 m
2
or above. In contrast with the findings for coronary
heart disease, however, only people with stage 3b or
stage 4 chronic kidney disease had a higher risk of
non-vascular mortality compared with the reference
group (fig 1, table 3). Hazard ratios were 0.97 (0.82
to 1.15) for mortality due to cancer and 1.26 (1.07 to
1.50) for mortality not attributed to cancer or vascular
disease, including deaths from renal failure (fig 2).
We found qualitatively similar findings to those
reported here in analyses that used Kidney Disease
Outcomes Quality Initiative criteria (web table D),
25
usedtheCKD-EPIequation(webtableE),usedacom-
peting risks model (web table F),
28 compared subtypes
of coronary heart disease (fig 2), excluded the initial
five years of follow-up (web fig C), and considered
the impact of undiagnosed new onset chronic kidney
disease (web fig D). Too few deaths from non-vascular
causes were available to allow us to subdivide out-
comes further. Similar considerations apply to the
small numbers of people who had proteinuria in
chronic kidney disease stages 3 and 4.
Chronic kidney disease and coronary heart disease risk
prediction
Addition of smoking status, systolic blood pressure,
total cholesterol, and diabetes to a coronary heart dis-
ease risk model containing only age (and stratified by
sex) increased the C index from 0.6453 to 0.6963.
Furtheradditionofinformationonchronickidneydis-
ease status increased the C index from 0.6963 to
0.6978, an increase of 0.0015 (0.0004 to 0.0026;
P=0.010) denoting correct prediction of the order of
coronary heart disease outcomes in a further 15 out of
10000pairsofparticipantsscreened.Additionofinfor-
mation on chronic kidney disease status to the risk fac-
tors listed above appropriately reclassified 5.3% of
participants who developed coronary heart disease
and 2.0% of participants who did not (web table G).
Table 3 |Association of renal function with coronary heart disease and non-vascular mortality
Renal function No
Coronary heart disease Non-vascular mortality
No of
events Ageandsexadjusted Further adjusted*
No of
events Ageandsexadjusted Further adjusted*
Participants without chronic kidney disease
eGFR ≥90 ml/min/1.73 m
2† 3265 872 1.09 (1.02 to 1.17) 1.11 (1.03 to 1.19) 803 1.15 (1.07 to 1.24) 1.13 (1.05 to 1.21)
eGFR 75-89 ml/min/1.73 m
2 6031 1478 1.00 (0.95 to 1.05) 1.00 (0.95 to 1.06) 1404 1.00 (0.95 to 1.06) 1.00 (0.95 to 1.06)
eGFR 60-74 ml/min/1.73 m
2† 5902 1319 1.04 (0.99 to 1.10) 1.02 (0.97 to 1.08) 1346 0.94 (0.89 to 0.99) 0.95 (0.90 to 1.00)
Participants with chronic kidney disease‡ ‡
Stage 1 (eGFR ≥90 ml/min/1.73 m
2 plus
proteinuria)†
63 22 1.77 (1.16 to 2.69) 1.55 (1.02 to 2.35) 13 1.37 (0.79 to 2.36) 1.33 (0.77 to 2.29)
Stage 2 (eGFR 60-89 ml/min/1.73 m
2 plus
proteinuria)
125 54 1.94 (1.49 to 2.54) 1.72 (1.30 to 2.24) 21 0.83 (0.54 to 1.27) 0.76 (0.50 to 1.17)
Stage 3a (eGFR 45-59 ml/min/1.73 m
2)† 908 240 1.44 (1.26 to 1.64) 1.39 (1.22 to 1.58) 258 1.03 (0.90 to 1.16) 1.06 (0.94 to 1.21)
Stage 3b (eGFR 30-44 ml/min/1.73 m
2)† 63 20 2.26 (1.45 to 3.51) 1.90 (1.22 to 2.96) 26 1.81 (1.23 to 2.67) 1.82 (1.24 to 2.68)
Stage 4 (eGFR 15-29 ml/min/1.73 m
2)† 12 5 6.46 (2.69 to 15.5) 4.29 (1.78 to 10.3) 4 6.40 (2.40 to 17.1) 5.97 (2.24 to 15.9)
eGFR=estimated glomerular filtration rate.
Analysis restricted to 16 369 participants with complete information on smoking status, history of diabetes, total cholesterol, triglycerides (log transformed), systolic blood pressure, and
body mass index.
*Additionally adjusted for smoking status, history of diabetes, total cholesterol, triglycerides (log transformed), systolic blood pressure, and body mass index.
†Reference group=people with eGFR 75-89 ml/min/m
2 and no proteinuria.
‡No participants in this cohort were in stage 5 or kidney failure stage (that is, eGFR <15 ml/min/1.73 m
2).
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Fig 1 | Renal function and risk of coronary heart disease and
non-vascular mortality. Hazard ratios are adjusted for age,
sex, smoking status, history of diabetes, total cholesterol, log
triglycerides, systolic blood pressure, and body mass index.
All hazard ratios are compared with people without chronic
kidney disease with estimated glomerular filtration rate
(eGFR) of 75-89 ml/min/1.73 m
2 and plotted against mean
eGFR within each group. Size of data markers is proportional
to inverse of variance of hazard ratios. Confidence intervals
are calculated using floating variances; eGFR is calculated
using MDRD equation
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account, however, the overall net reclassification
improvement was 1.04% (−0.93% to 3.02%; P=0.301).
When we calculated the average absolute improve-
ment in prediction of risk without categorisation into
riskgroups,theintegratedimprovementindiscrimina-
tion was 0.0022 (0.0010 to 0.0033; P<0.001). This
denotes an improvement equivalent to about 0.2% in
predictedabsoluteriskforatypicalscreenedpersonon
addition of information on chronic kidney disease sta-
tus to other risk factors.
Compared with a model containing several conven-
tional risk factors plus chronic kidney disease status,
the C index decreased by 0.0015 (P=0.010) after
removal of chronic kidney disease, by 0.0024
(P=0.002) after removal of diabetes, and by 0.0124
(P<0.001) after removal of smoking status (table 4).
The decrease in the integrated discrimination
improvement score was 0.0022 (P<0.001) after
removal of chronic kidney disease, 0.0016 (P=0.017)
after removal of diabetes, and 0.0063 (P<0.001) after
removal of smoking status. The corresponding
decrease in the net reclassification improvement was
1.04% (P=0.30) after removal of chronic kidney dis-
ease, 2.34% (P=0.003) after removal of diabetes, and
6.77% (P<0.001) after removal of smoking status. The
incremental value of information on chronic kidney
diseasestatuswaslowerwhenaddedtomoreelaborate
risk prediction models that used information on addi-
tional risk factors.
DISCUSSION
For people without manifest vascular disease, we have
shown that even the earliest stages of chronic kidney
disease are associated with higher risk of coronary
heart disease. In people without clinically defined
chronic kidney disease, however, lower estimated glo-
merular filtration rate was not significantly associated
with risk of coronary heart disease. Hence, in contrast
with blood pressure and total cholesterol, which each
have log-linear relations with risk of coronary heart
disease across their range of values,
29 estimated glo-
merular filtration rate seems to be non-linearly related
toriskofcoronaryheartdisease.Theriskthresholdfor
estimatedglomerularfiltrationrateseemstobenearto
60 ml/min/1.73 m
2, or the value that clinically defines
chronic kidney disease. The lack of an appreciable
changeinassociationsinanalysesthatexcludedpeople
with diabetes at entry, omitted initial follow-up, or
adjustedforseveralcardiovascularriskfactorssuggests
that our results are robust. However, although plausi-
ble mechanisms have been proposed to suggest that
impaired kidney function may itself be a causal factor
incoronaryheartdisease,
30thepossibilityremainsthat
chronickidneydiseaseischieflyamarkerofunfavour-
able cardiovascular risk profiles. We also found that
advanced stages of chronic kidney disease were signif-
icantly associated with the aggregate of non-vascular
mortality, particularly deaths not attributed to cancer
(including, unsurprisingly, those related to end stage
renal disease itself
14).
Our othermain findingisthat assessment ofchronic
kidney disease status in a general middle aged popula-
tion onlymodestlyimprovespredictionof riskforcor-
onary heart disease when information is available on
conventional cardiovascularriskfactors.Forexample,
the clinically relevant incremental gain provided by
chronic kidney disease was about half that provided
by history of diabetes and about a sixth that provided
by history of smoking. Hence, although assessment of
chronic kidney disease is potentially practicable on a
population-wide basis (as it involves relatively simple
blood and urine tests), further studies in other popula-
tions are needed to determine whether its use for
screening for cardiovascular disease would be suffi-
ciently informative to justify the cost and effort. In
Table 4 |Change in metrics of coronary heart disease risk prediction on removal of chronic
kidney disease, history of diabetes, or smoking status from a model containing other
conventional risk factors
Factor omitted
Discrimination: decrease in C
index (P value)
Reclassification
IDI (P value) % NRI (P value)
Chronic kidney disease 0.0015 (0.010) 0.0022 (<0.001) 1.04 (0.301)
History of diabetes 0.0024 (0.002) 0.0016 (0.017) 2.34 (0.003)
Smoking status 0.0124 (<0.001) 0.0063 (<0.001) 6.77 (<0.001)
Full model with conventional risk factors (stratified by sex) includes age, smoking status (current v other),
history of diabetes (yes v no), total cholesterol, systolic blood pressure, and chronic kidney disease (yes v no).
IDI=integrated discrimination index; NRI=net reclassification improvement.
Coronary heart disease
  Non-fatal myocardial infarction
  Coronary death
  Coronary revascularisation
All
Other vascular mortality
  Ischaemic stroke
  Haemorrhagic stroke
  Unclassified stroke
  Other cerebrovascular deaths
  Other cardiovascular deaths
All
Non-vascular mortality
  All cancer deaths
  Non-cancer deaths
All
Deaths of unknown causes
All cause mortality
1.47 (1.24 to 1.73)
1.21 (0.98 to 1.48)
1.54 (1.17 to 2.01)
1.45 (1.29 to 1.62)
1.21 (0.75 to 1.95)
1.02 (0.55 to 1.89)
1.18 (0.77 to 1.80)
0.71 (0.37 to 1.33)
1.22 (0.89 to 1.66)
1.11 (0.92 to 1.36)
0.97 (0.82 to 1.15)
1.26 (1.07 to 1.50)
1.10 (0.98 to 1.24)
1.27 (0.54 to 3.00)
1.13 (1.03 to 1.23)
1877
1143
990
4010
176
156
227
171
491
1221
2289
1586
3875
83
6322
0.5 1 2 4
Outcome Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
No of
events
Fig 2 | Risk of vascular and non-vascular outcomes in people with chronic kidney disease
compared with people without chronic kidney disease. Analysis restricted to participants with
complete information on smoking status, history of diabetes, total cholesterol, triglycerides
(log transformed), systolic blood pressure, and body mass index. Hazard ratios are adjusted
for age, sex, smoking status, history of diabetes, systolic blood pressure, total cholesterol, log
triglycerides, and body mass index. Size of data markers is proportional to inverse of variances
of hazard ratios
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lence of chronic kidney disease and other risk factors
mightyielddifferentresultsfortheincrementalpredic-
tive value of information on chronic kidney disease
status.
Strengths and limitations
We identified participants in population registers,
achieved high response and follow-up rates, and used
standardmethodstoassayserumcreatinine.Neverthe-
less, our study had potential limitations. Our partici-
pants were of northern European descent, so the
findings may not apply to other races. Although we
usedstandardpredictionequationstoestimateglomer-
ular filtration rate, they were originally developed in
patients with kidney disease.
31 We used qualitative
urinary dipstick methods routinely used in clinical
practice, but quantitative methods should be more
sensitive.
32 We did not have serial measurements on
creatinine concentration or urinary protein. Although
sensitivity analyses suggest that our results would be
little affected by plausible rates of new onset chronic
kidney disease, lack of correction for within person
variability could have resulted in bias. Although we
used robust methods to ascertain disease outcomes,
22
preferential diagnoses in people known to have
chronic kidney disease may have resulted in overesti-
mation of hazard ratios. By contrast, some random
misclassification inherent in using disease registers
would have underestimated associations.
Conclusion
In people without manifest vascular disease, even the
earliest stages of chronic kidney disease are associated
with excess risk of subsequent coronary heart disease.
Assessment of chronic kidney disease in addition to
conventional risk factors modestly improves predic-
tion of risk for coronary heart disease. Further studies
areneededtoinvestigateassociationsbetweenchronic
kidneydiseaseandnon-vascularmortalityfromcauses
other than cancer.
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